Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 77 of 118 for:    Atenolol

Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function (TREAT-SVDs)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03082014
Recruitment Status : Recruiting
First Posted : March 17, 2017
Last Update Posted : August 14, 2019
Sponsor:
Collaborators:
University of Edinburgh
Maastricht University Medical Center
UMC Utrecht
University of Oxford
Information provided by (Responsible Party):
Martin Dichgans, Ludwig-Maximilians - University of Munich

Tracking Information
First Submitted Date  ICMJE March 8, 2017
First Posted Date  ICMJE March 17, 2017
Last Update Posted Date August 14, 2019
Actual Study Start Date  ICMJE February 22, 2018
Estimated Primary Completion Date March 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 16, 2017)
Change from Baseline Cerebrovascular Reactivity (CVR) at 4 weeks of Monotherapy [ Time Frame: baseline measure at the end of the run-in phase (week 2); after 4 weeks of each monotherapy (week 6, week 10, and week 14) ]
The primary outcome variable is CVR as determined by blood oxygen level-dependent (BOLD) MRI (T2*) brain scan response to hypercapnic challenge at the end of the 2 week run-in phase and after 4 weeks of monotherapy while still on medication.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 16, 2017)
  • Change from Baseline Mean Systolic Blood Pressure (SBP) at the last week of each treatment phase [ Time Frame: within the last week of the run-in phase and within the last week of each treatment phase ]
    Mean SBP assessed by daily telemetric monitoring within the last week of the run-in phase and within the last week of each treatment phase
  • Change from Baseline Blood Pressure Variability (BPv) at the last week of each treatment phase [ Time Frame: within the last week of the run-in phase and within the last week of each treatment phase ]
    BPv operationalized as coefficient of variation (100*std/mean SBP) across multiple measurements and assessed by daily telemetric monitoring within the last week of the run-in phase and within the last week of each treatment phase
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function
Official Title  ICMJE EffecTs of Amlodipine and Other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases
Brief Summary

Multicentre, multinational, prospective randomised, open-label, 3 sequence crossover phase III b clinical trial with blinded endpoint assessment (PROBE-design)

  • in 75 patients with sporadic small vessel diseases (SVDs) and
  • in 30 patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Detailed Description

TREAT-SVDs will be carried out as a multicentre open label trial at five trial sites across 3 European countries: Germany, the Netherlands, and the United Kingdom.

Patients meeting eligibility criteria will be randomly allocated to one of three sequences of antihypertensive treatment which are given as open-label oral medications in standard dose in the following order

Arm A: Amlodipine > Losartan > Atenolol

Arm B: Atenolol > Amlodipine > Losartan

Arm C: Losartan > Atenolol > Amlodipine.

The study starts with a two week run-in phase. During these first two weeks, patients are not allowed to take antihypertensive drugs except for the rescue medication. After the run-in period,every patient will take subsequently three different antihypertensive drugs (each drug from a separate drug class) according to the randomly assigned arm. Each study drug will be administered for four weeks.

Patients will be monitored telemetrically with a dedicated BP device during the whole trial period of 14 weeks.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
TREAT-SVDs is a multi-centre, multinational phase III b clinical trial with a three sequence crossover design. It will be carried out as a rater blinded trial which is also known as PROBE-design (prospective, randomised, open-label trial with blinded endpoint assessment).
Masking: Single (Outcomes Assessor)
Masking Description:
Cerebrovascular reactivity measures will be assessed centrally by a blinded rater.
Primary Purpose: Treatment
Condition  ICMJE Cerebral Small Vessel Diseases
Intervention  ICMJE
  • Drug: Amlodipine
    blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
  • Drug: Losartan
    blood pressure lowering agent - angiotensin-receptor blockers
  • Drug: Atenolol
    blood pressure lowering agent - beta-blocker
Study Arms  ICMJE
  • Active Comparator: Arm A
    Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
    Interventions:
    • Drug: Amlodipine
    • Drug: Losartan
    • Drug: Atenolol
  • Active Comparator: Arm B
    Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
    Interventions:
    • Drug: Amlodipine
    • Drug: Losartan
    • Drug: Atenolol
  • Active Comparator: Arm C
    Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
    Interventions:
    • Drug: Amlodipine
    • Drug: Losartan
    • Drug: Atenolol
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 16, 2017)
105
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 30, 2020
Estimated Primary Completion Date March 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Patients may be enrolled in the trial if all of the following criteria have been met:

  • Symptomatic SVD defined as

    • History of clinical lacunar stroke in the last 5 years with a corresponding small subcortical infarct visible on MRI scan or CT scan* compatible with the clinical syndrome.

      *On MRI, recent infarct is defined as a diffusion-weighted imaging (DWI) lesion on the acute MRI scan. On CT, recent infarct is defined as a novel infarct on CT within 3 weeks after the event that was not visible on the admission CT. Patients admitted to the hospital with an obvious lacunar syndrome and an admission CT/CT perfusion compatible with a lacunar infarct but without an MRI in the (sub)acute stage and no repeat CT performed in the context of clinical care can be recruited for TREAT-SVDs. After providing informed consent they will be invited for the screening visit including a 3T MRI. The 3T MRI will be used to verify the presence of a new lesion, relative to the admission CT, compatible with a lacunar infarct and compatible with the lacunar syndrome. If such a lesion is present the patient will undergo the further TREAT-SVDs workup. If no such lesion is observed the patient will be excluded from the study and considered as a screening failure.

    • or cognitive impairment defined as visiting a memory clinic with cognitive complaints, objective cognitive impairment*, and capacity to consent, and with confluent deep white matter hyperintensities (WMH) on MRI (defined on the Fazekas scale as deep WMH score ≥ 2)

      *concluded by the treating physician based on a validated cognitive measurement tool (for example but not limited to MoCA or CAMCOG)

    • or a diagnosis of CADASIL established by molecular genetic testing of the NOTCH3 gene (presence of an archetypical, cysteine-affecting mutation) or the presence of granular osmiophilic material in ultrastructural, electron microscopy analysis of skin biopsy
  • Indication for antihypertensive treatment (as defined by meeting one of the following):

    • Hypertension defined as SBP ≥ 140 mmHg or diastolic BP (DBP) ≥ 90 mmHg without antihypertensive treatment or use of an antihypertensive drug for previously diagnosed hypertension
    • Prior history of stroke or transient ischaemic attack (TIA)
  • Age 18 years or older
  • Written informed consent

Exclusion Criteria:

Patients will be excluded from the trial for any of the following reasons:

  • Inclusion criteria are not met
  • Unwillingness or inability to give written consent
  • Pregnant or breastfeeding women, women of childbearing age not taking contraception.

Acceptable contraception in women of childbearing age is a "highly effective" contraceptive measure as defined by the Clinical Trials Facilitation Group and includes combined (oestrogen and progesterone containing) or progesterone-only contraception associated with inhibition of ovulation, or intrauterine device, or bilateral tubal occlusion.

  • Contraindications to MRI (pacemaker, aneurysm clip, cochlear implant etc.)
  • Other major neurological or psychiatric conditions affecting the brain and interfering with the trial design (e.g. multiple sclerosis)
  • In case of clinical lacunar stroke syndrome other causes of stroke such as

    • ≥ 50% luminal stenosis (NASCET) in large arteries supplying the area of ischaemia
    • major-risk cardioembolic source of embolism (permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, atrial myxoma or other cardiac tumours, mitral stenosis, recent (< 4 weeks) myocardial infarction, left ventricular ejection fraction less than 30%, valvular vegetations, or infective endocarditis)
    • other specific causes of stroke identified (e.g. arteritis, dissection, migraine/vasospasm, drug misuse)
  • Other stroke risk factor requiring immediate intervention that would preclude involvement in the trial
  • Renal impairment (eGFR < 35ml/min)
  • Life expectancy < 2 years
  • Use of > 2 antihypertensive drugs at maximum dose or equivalent (one drug at the maximum dose and two drugs at half of the maximum dose) for an appropriate BP control
  • Contraindications to the applied antihypertensive drugs as known

    • Severe aortic stenosis
    • Bilateral renal artery stenosis
    • Severe arterial circulatory disorders
    • Atrioventricular block II° or III° or sick sinus syndrome
    • Heart failure (NYHA III or IV)
    • Bradycardia, resting heart rate < 50/min
    • Bronchospastic diseases such as severe bronchial asthma
    • Severe hepatic dysfunction such as liver cirrhosis
    • Use of monoamine oxidase (MAO)-A-blockers
    • Use of simvastatin > 20mg/d
    • Metabolic acidosis
    • Disturbed electrolyte homeostasis such as hypercalcaemia, hypokalaemia, and hyponatraemia
    • Symptomatic hyperuricaemia (gout)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Anna Kopczak, Dr. +49 (0)89 4400 ext 46125 anna.kopczak@med.uni-muenchen.de
Listed Location Countries  ICMJE Germany,   Netherlands,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03082014
Other Study ID Numbers  ICMJE TRE-1486--0105-I
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Martin Dichgans, Ludwig-Maximilians - University of Munich
Study Sponsor  ICMJE Ludwig-Maximilians - University of Munich
Collaborators  ICMJE
  • University of Edinburgh
  • Maastricht University Medical Center
  • UMC Utrecht
  • University of Oxford
Investigators  ICMJE
Study Director: Martin Dichgans, Prof. Institute for Stroke and Dementia Research
Principal Investigator: Joanna Wardlaw, Prof. Neuroimaging Sciences and Brain Research Imaging Centre
Principal Investigator: Robert van Oostenbrugge, Prof. Maastricht University Medical Center (UM), Department of Neurology
Principal Investigator: Geert Jan Biessels, Prof. UMC Utrecht Brain Center Robert Magnus (UMCU)
Principal Investigator: Peter Rothwell, Prof. Nuffield Department of Clinical Neurosciences, Oxford (UOXF)
PRS Account Ludwig-Maximilians - University of Munich
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP